Kaida BioPharma Announces Formation of Scientific Advisory Board to Support Development of KAD101 for Ovarian Cancer
19 nov. 2024 09h15 HE
|
Kaida Biopharma
Company appoints Anil K. Sood, MD, as inaugural member Company continues to advance lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1 study, targeted for 2025...
Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts
26 sept. 2024 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces dosing of the first subjects in the multiple-ascending dose (MAD)...
Kaida BioPharma Launches Social Media Channels
18 sept. 2024 10h00 HE
|
Kaida Biopharma
Company dedicated to providing a new hope for patients with treatment-resistant gynecological cancers Lead program, KAD101 for the treatment of ovarian cancer rapidly advancing towards Phase 1...
Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
18 sept. 2024 08h30 HE
|
Sonnet BioTherapeutics Holdings, Inc.
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’ Topline safety data of SB101 Phase 1 study expected by Q4 2024 PRINCETON, NJ, Sept. 18, 2024 (GLOBE...
Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor
18 juil. 2024 08h00 HE
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., July 18, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) today reported favorable safety and tolerability results from the...
Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09 avr. 2024 16h35 HE
|
Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
28 mars 2024 08h00 HE
|
Cocrystal Pharma, Inc.
FDA feedback following the Company’s submission of a Pre-IND briefing package improves clarity on regulatory requirements for Phase 2b influenza A clinical trial with oral CC-42344, a broad-spectrum...
QSAM Biosciences Receives Clearance from FDA to Expand Enrollment Criteria in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
08 mars 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, March 08, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
QSAM Biosciences Completes Enrollment of Initial Cohort in its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer
28 févr. 2023 08h00 HE
|
QSAM Biosciences Inc.
Austin, TX, Feb. 28, 2023 (GLOBE NEWSWIRE) -- QSAM Biosciences Inc. (OTCQB: QSAM), a company developing next generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP (CycloSam®),...
BioNTech beginnt Phase-1-Studie mit prophylaktischem Impfstoffkandidaten BNT163 gegen Herpes-Simplex-Virus-2
21 déc. 2022 06h45 HE
|
BioNTech SE
Erste klinische Studie untersucht Sicherheit und Immunogenität des prophylaktischen Herpes-Virus-Impfstoffkandidaten BNT163 erstmalig am MenschenBNT163 ist der erste Kandidat aus BioNTechs...